Certara

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Certara surpasses revenue expectations, eyes global expansion and innovation

Certara's strong financial performance in Q4 2022 and exceeding revenue guidance for the full year underscore the company's growth trajectory and market positioning.
With a focus on software, biosimulation services, and global expansion, Certara is poised for continued success in 2023 and beyond.
The company's proactive engagement with regulatory bodies, strategic acquisitions, and partnerships signal a commitment to innovation and sustainable growth.

Certara reports robust Q1 earnings driven by biosimulation strength

Certara's Q1 2023 showcased solid financial performance, particularly in software and biosimulation services. Despite challenges in deal closure times and subscription model impact, the company remains optimistic about future growth opportunities.

Certara reports solid Q2 earnings, eyes growth through AI integration

Certara's Q2 performance showed growth in both software and services revenue, with adjusted EBITDA at $32.4 million.
The company faces challenges from cautious spending and slow recovery in regulatory business but remains optimistic about long-term industry potential.
Strengths include acquisitions enhancing AI capabilities, focus on accelerating projects, and expanding key offerings.
Opportunities lie in integrating AI, driving growth in biosimulation services, and aiming for higher growth in 2024.

Certara reports stable Q3 performance, eyes growth in biosimulation and AI

Certara's Q3 performance showed revenue growth driven by software, despite challenges in services revenue.
The company remains confident in its strategies and outlook for growth, focusing on biosimulation and AI integration.
While facing uncertainties in closing AI product deals, Certara sees opportunities in market demand and long-term growth.
Analysts' inquiries during the call highlighted areas of concern but also underscored Certara's strengths and potential for expansion.

Certara reports steady revenue growth, eyes software investments for 2024

Certara's Q4 2023 performance reflects a mixed revenue picture with software revenue growth offsetting a decline in services revenue, while the company maintains a strong financial position.
Strategic acquisitions, growth initiatives in key markets, and a focus on operational efficiency present avenues for Certara to drive future growth and enhance market competitiveness.
Challenges lie in balancing revenue streams, managing margin pressures from investments, and navigating market uncertainties, requiring strategic decision-making and operational agility.
Overall, Certara's outlook for 2024 is optimistic, underpinned by confidence in growth drivers, strategic acquisitions, and a commitment to innovation and market expansion.

Certara reports solid Q1 performance and eyes revenue acceleration

Certara's Q1 performance reflects growth in software revenue and steady services revenue, with a focus on operational efficiency and strategic goals for 2024.
Challenges include seasonality in services bookings and the need for further restructuring, while opportunities lie in potential revenue acceleration and market dynamics.
Overall, Certara remains optimistic for the year ahead, maintaining revenue and EPS guidance for 2024 and aiming for margin improvement in the second half.

Certara reports Q2 revenue growth, acquires Chemaxon for innovation

Certara's Q2 performance showed mixed results with revenue growth driven by Software but offset by a decline in Services, while bookings and adjusted EBITDA demonstrated positive momentum.
The company's strategic strengths lie in recent acquisitions, product innovations, and a focus on software and AI investments to drive future growth and profitability.
Challenges include addressing declines in the Services segment, improving performance with Tier 1 customers, and managing operational costs to reduce net losses.
Opportunities for Certara include meeting full-year revenue guidance, leveraging software and AI investments for industry leadership, and expanding market presence through recent acquisitions and product releases.

Certara reports strong Q3 earnings, focuses on biosimulation growth

Certara's Q3 performance was strong, driven by revenue growth and strategic investments in software and commercial reach.
While facing challenges in the regulatory services market, Certara is focused on leveraging opportunities from the Chemaxon acquisition and uniting R&D and sales efforts for sustainable growth.
The company's financial position is robust with healthy cash reserves, but managing debt levels and maintaining margins in regulatory services remain key challenges.
Certara's outlook for 2024 is positive, with updated guidance indicating revenue of $380-385 million and adjusted EBITDA of $120-124 million.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.

PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City. Certara's management team will provide updates on the Company's strategy, differentiated software and technology-driven services, and financial guidance for 2022. There will also be a demonstration of the Simcyp™ Simulator.

Certara to Host Investor Day on December 15, 2021

Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs

Certara Announces Update of D360™ Scientific Informatics Software

PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Certara Announces Closing of Public Offering of Common Stock

The stock price of Certara Inc (NASDAQ: CERT) fell by over 10% pre-market today. This is why it happened.

Certara (CERT) Stock: Why The Price Dropped Today

PRINCETON, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (the “selling stockholders”) at a price to the public of $31.00 per share. Additionally, the selling stockholders have granted the underwriters a 30-day option to purchase up to 1.5 million additional shares of common stock. Certara is not selling any shares and will not receive any proceeds from the sale of shares in the offering by the selling stockholders. The offering is expected to close on or about November 22, 2021, subject to customary closing conditions.

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 1.5 million additional shares of common stock. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Certara Announces Proposed Public Offering of Common Stock

Certara Inc. (CERT) CEO William Feehery on Q3 2021 Results - Earnings Call Transcript

Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21

Certara Reports Third Quarter 2021 Financial Results

High-tech CEO with decades of experience supports continued innovation and growth High-tech CEO with decades of experience supports continued innovation and growth

Certara Appoints James E. Cashman III as Chairman of Board of Directors

PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

Pinnacle 21 Enterprise software expedites regulatory review of all study submission data Pinnacle 21 Enterprise software expedites regulatory review of all study submission data

Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services

Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Software/Services category Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Software/Services category

Certara's Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021

PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery. Dr. Smith will lead the Company's global drug development services team, which creates value for clients across the entire drug development life cycle using biosimulation and quantitative approaches. Dr. Smith succeeds Craig R. Rayner, Pharm.D., who has served as president of IDD since 2019 and will be appointed to the role of Certara distinguished scientist, leading key strategic client engagements and scientific innovation.

Certara Appoints Patrick F. Smith to President of Integrated Drug Development

Experienced commercial leader brings 20 years of experience in pharma Experienced commercial leader brings 20 years of experience in pharma

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Complementary technologies accelerate and help assure success in the drug development process Complementary technologies accelerate and help assure success in the drug development process

Certara Completes Acquisition of Pinnacle 21

Cloud-based and validated regulatory software automates and advances quality of patient narratives Cloud-based and validated regulatory software automates and advances quality of patient narratives

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term

Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock. Certara sold 4,500,000 shares of its common stock, and certain selling stockholders sold 18,500,000 shares of common stock in the offering. The gross proceeds to Certara from the offering were approximately $139.5 million, before deducting the underwriting discount and offering expenses. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

The stock price of Certara Inc (NASDAQ: CERT) dropped over 7% pre-market this morning. This is why it happened.

CERT Stock: Why It Is Trading Lower Today

Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represents a discount of almost 12% from the last close price of $35.14 on Wednesday.

Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount

Certara Inc's (CERT) CEO William Feehery on Q2 2021 Results - Earnings Call Transcript

News for Certara Stock (CERT)